Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023
- PMID: 37227984
- PMCID: PMC10231940
- DOI: 10.15585/mmwr.mm7221a3
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023
Abstract
On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least a monovalent primary series. Early vaccine effectiveness (VE) estimates among adults aged ≥18 years showed receipt of a bivalent booster dose provided additional protection against COVID-19-associated emergency department and urgent care visits and hospitalizations compared with that in persons who had received only monovalent vaccine doses (1); however, insufficient time had elapsed since bivalent vaccine authorization to assess the durability of this protection. The VISION Network* assessed VE against COVID-19-associated hospitalizations by time since bivalent vaccine receipt during September 13, 2022-April 21, 2023, among adults aged ≥18 years with and without immunocompromising conditions. During the first 7-59 days after vaccination, compared with no vaccination, VE for receipt of a bivalent vaccine dose among adults aged ≥18 years was 62% (95% CI = 57%-67%) among adults without immunocompromising conditions and 28% (95% CI = 10%-42%) among adults with immunocompromising conditions. Among adults without immunocompromising conditions, VE declined to 24% (95% CI = 12%-33%) among those aged ≥18 years by 120-179 days after vaccination. VE was generally lower for adults with immunocompromising conditions. A bivalent booster dose provided the highest protection, and protection was sustained through at least 179 days against critical outcomes, including intensive care unit (ICU) admission or in-hospital death. These data support updated recommendations allowing additional optional bivalent COVID-19 vaccine doses for certain high-risk populations. All eligible persons should stay up to date with recommended COVID-19 vaccines.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Brian E. Dixon reports grant support from the National Institutes of Health, the U.S. Agency for Healthcare Research and Quality, and the U.S. Department of Veterans Affairs to evaluate health information exchange (HIE) technologies; royalties from Elsevier for book on HIE and from Springer Nature for book on public health informatics; and consulting fees from Merck and Co. for participating on a human papillomavirus vaccine advisory panel. Allison L. Naleway reports institutional support from Pfizer for an unrelated study of meningococcal B vaccine safety during pregnancy and from Vir Biotechnology for an unrelated influenza study. No other potential conflicts of interest were disclosed.
Similar articles
-
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1335-1342. doi: 10.15585/mmwr.mm7142a4. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36264840 Free PMC article.
-
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.MMWR Morb Mortal Wkly Rep. 2023 Mar 17;71(53):1637-1646. doi: 10.15585/mmwr.mm7153a1. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36921274 Free PMC article.
-
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1616-1624. doi: 10.15585/mmwr.mm715152e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36580430 Free PMC article.
-
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081. Epidemiol Prev. 2023. PMID: 38314543 Review. English.
-
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.Vaccine. 2024 May 31;42(15):3389-3396. doi: 10.1016/j.vaccine.2024.04.049. Epub 2024 Apr 22. Vaccine. 2024. PMID: 38653679 Review.
Cited by
-
The Limitations of a Hypothetical All-Variant COVID-19 Vaccine: A Simulation Study.Vaccines (Basel). 2024 May 13;12(5):532. doi: 10.3390/vaccines12050532. Vaccines (Basel). 2024. PMID: 38793783 Free PMC article.
-
COVID-19 Vaccination Strategies in the Endemic Period: Lessons from Influenza.Vaccines (Basel). 2024 May 9;12(5):514. doi: 10.3390/vaccines12050514. Vaccines (Basel). 2024. PMID: 38793765 Free PMC article. Review.
-
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
-
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity.Front Immunol. 2024 May 2;15:1397040. doi: 10.3389/fimmu.2024.1397040. eCollection 2024. Front Immunol. 2024. PMID: 38756784 Free PMC article. Review.
-
Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection among Kidney Transplant Recipients: A Large Single-Center Experience.Crit Care Res Pract. 2024 May 2;2024:7140548. doi: 10.1155/2024/7140548. eCollection 2024. Crit Care Res Pract. 2024. PMID: 38725586 Free PMC article.
References
-
- Tenforde MW, Weber ZA, Natarajan K, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION Network, nine states, September–November 2022. MMWR Morb Mortal Wkly Rep 2023;71:1637–46. 10.15585/mmwr.mm7153a1 - DOI - PMC - PubMed
-
- Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:139–45. 10.15585/mmwr.mm7104e3 - DOI - PMC - PubMed
-
- DeCuir J, Surie D, Zhu Y, et al.; IVY Network. Effectiveness of monovalent mRNA COVID-19 vaccination in preventing COVID-19–associated invasive mechanical ventilation and death among immunocompetent adults during the Omicron variant period—IVY Network, 19 U.S. states, February 1, 2022–January 31, 2023. MMWR Morb Mortal Wkly Rep 2023;72:463–8. 10.15585/mmwr.mm7217a3 - DOI - PubMed
-
- Britton A, Embi PJ, Levy ME, et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19–associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance—VISION Network, 10 states, December 2021–August 2022. MMWR Morb Mortal Wkly Rep 2022;71:1335–42. 10.15585/mmwr.mm7142a4 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous